Format

Send to

Choose Destination
Br J Dermatol. 2011 Jan;164(1):192-6. doi: 10.1111/j.1365-2133.2010.10081.x. Epub 2010 Nov 29.

Maggot chymotrypsin I from Lucilia sericata is resistant to endogenous wound protease inhibitors.

Author information

1
Immune Modulation Research Group, School of Pharmacy, University of Nottingham, Nottingham NG7 2RD, UK.

Abstract

BACKGROUND:

A chymotrypsin found in the secretions of Lucilia sericata and manufactured as a recombinant enzyme degrades chronic wound eschar ex vivo.

OBJECTIVES:

To characterize the inhibition profile of the L. sericata recombinant chymotrypsin I.

METHODS:

Activity of recombinant chymotrypsin I and its sensitivity to endogenous inhibitors were determined enzymatically using the fluorogenic substrate succinyl-alanyl-alanyl-prolyl-phenylalanyl-aminomethyl coumarin.

RESULTS:

We report the presence of high concentrations of two endogenous inhibitors, α1-antichymotrypsin and α1-antitrypsin, in wound eschar and a trace of a third, α2-macroglobulin, with the potential to inhibit this debridement process. However, the addition of a soluble and inhibitor-containing extract of chronic wound eschar to chymotrypsin I did not affect activity of the enzyme, neither did the addition of purified native α1-antichymotrypsin or α1-antitrypsin, although chymotrypsin I was inhibited by α2-macroglobulin. Conversely, the mammalian equivalent, α-chymotrypsin, was inhibited by the purified native α1-antichymotrypsin, α1-antitrypsin and α2-macroglobulin and by the soluble extract of wound eschar.

CONCLUSIONS:

The data suggest that the maggot-derived chymotrypsin I is biochemically distinct from human α-chymotrypsin and the lack of inhibition by wound eschar suggests a means by which chymotrypsin I activity survives within the wound to contribute towards debridement during maggot biotherapy.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center